| OTSUKA-PHARMACEUTICAL-CO-LTD |
OTSUKA-PHARMACEUTICAL-CO-LTD |
90%
|
As of March 31, 2026, the Company had $ 4.4 million due from Otsuka Pharmaceutical Co., Ltd. ("Otsuka") related to the estimated cost sharing and reimbursement. |
| ARCT |
Arcturus Therapeutics Holdings Inc. |
72%
|
Reciprocal relationship from ARCT graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from ARCT graph: Reciprocal relationship from FDMT graph: val of a product or impose restrict… |
| ARCT |
Arcturus Therapeutics Holdings Inc. |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictio… |
| JNJ |
Johnson & Johnson |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| KOD |
Kodiak Sciences Inc. |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| KOD |
Kodiak Sciences Inc. |
72%
|
Reciprocal relationship from KOD graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain time… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY grap… |
| LLY |
Eli Lilly and Company |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| RGNX |
REGENXBIO Inc. |
72%
|
Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| SNYNF |
Sanofi |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain ti… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from FDMT graph: val of a product or impose restrict… |
| AEVITAS-THERAPEUTICS-INC |
AEVITAS-THERAPEUTICS-INC |
62%
|
$ 3.0 million during the three months ended March 31, 2026. The transaction price amount allocated to unsatisfied or partially unsatisfied performance obligations as of March 31, 2026 was approximate… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
in stockholders over a rolling three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards (“NOLs”) and other pre-change tax attributes to offset its post-cha… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
t candidates at an earlier stage of development or on less favorable terms than we would otherwise 32 choose. We cannot assure you that we will ever be profitable or generate positive cash flow from … |
| LICENSE-ARRANGEMENTS-AEVITAS-THERAPEUTICS-INC |
LICENSE-ARRANGEMENTS-AEVITAS-THERAPEUTICS-INC |
62%
|
$ 3.0 million during the three months ended March 31, 2026. The transaction price amount allocated to unsatisfied or partially unsatisfied performance obligations as of March 31, 2026 was approximate… |
| MOLECULAR-THERAPEUTICS-INC |
MOLECULAR-THERAPEUTICS-INC |
62%
|
novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherw… |
| REIGNITE-THERAPEUTICS-INC |
REIGNITE-THERAPEUTICS-INC |
62%
|
ts have an exercise price of $ 0.0001 per underlying share of common stock of the Company. The shares of common stock into which the Pre-funded Warrants may be exercised are considered outstanding fo… |
